NEURODEGENERATIVE DISEASES:
BIOLOGY & THERAPEUTICS
November 30 - December 3, 2006
Abstract Deadline: September 15, 2006

Organizers:
Sam Gandy, Thomas Jefferson University
Virginia Man-Yee Lee, University of Pennsylvania
Marcy MacDonald, Massachusetts General Hospital
Peter J. Snyder, University of Connecticut

past program

You are cordially invited to participate in the fourth meeting on Neurodegenerative Diseases, which will be held at Cold Spring Harbor Laboratory. The meeting will begin with dinner and the first session on the evening of Thursday, November 30, and will conclude with lunch on Sunday, December 3, 2006.

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas.

This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Proposed Topics:
Triplet Repeat Diseases
Tauopathies
Synucleinopathies
Cerebral Amyloidoses
Amyotrophic Lateral Sclerosis
Mechanisms of Neurodegeneration
Current Therapies and Prevention
Cell and Gene Transfer
Genetics, Genomics & Patient Selection
Innovative Clinical Study Design

Confirmed Speakers:
Paul Aisen, Georgetown University Medical Center
Christopher Austin, National Institutes of Health/NHGRI
Elizabeth Aylward, University of Washington
Ronald Black, Wyeth Research
Roscoe Brady, National Institutes of Health/NINDS
Don Cleveland, University of California, San Diego
John Houston, Bristol-Myers Squibb
Clifford Jack, Mayo Clinic & Foundation
Grant Krafft, Acumen Pharmaceuticals, Inc.
Michael Krams, Wyeth Research
Douglas Macdonald, CHDI, Inc./MRSSI, Inc.
Paul Maruff, CogState Ltd.
Chester Mathis, UPMC Presbyterian Hospital
Amy McGuire, Foundation for the National Institutes of Health
Mike Miller, Colorado Division of Wildlife
Henry Paulson, University of Iowa Hospital and Clinics
Livio Pellizzoni, Institute of Cell Biology, Italy
Eric Reiman, University of Arizona
Herminia Rosas, Masschusetts General Hospital
Jeffrey Rothstein, Johns Hopkins University School of Medicine
Christopher Rowe, Austin Hospital, Australia
Leslie Shaw, University of Pennsylvania
Scott Small, Columbia University
Holly Soares, Pfizer Global Research & Development
Toshiharu Suzuki, Hokkaido University, Japan
Rudolph Tanzi, Massachusetts General Hospital
Linda Van Eldik, Northwestern University Feinberg School of Medicine
Kenton Zavitz, Myriad Pharmaceuticals, Inc.

Abstracts should contain new and unpublished material. Selection of material for oral and poster presentation will be made by the organizers and individual session chairs. Status (talk/poster) of abstracts will be posted on our website as soon as decisions have been made by the organizers. Please bring this notice to the attention of any of your colleagues who may be interested.

We are eager to have as many young people as possible attend since they are likely to benefit most from this meeting. We have applied for funds from government and industry to partially support graduate students and postdocs. Please note that a number of scholarships are likely to be available for women and underepresented minorities though the auspices of the National Institute of General Medical Sciences. Please register and apply in writing to meetings@cshl.edu stating eligibility and need.

We look forward to seeing you at Cold Spring Harbor in November/December.

---

Regular packages are all inclusive and cover registration, food, housing, parking, wine-and-cheese party, lobster banquet, etc. No Housing packages include all costs except housing. Full payment is due 4 weeks prior to the meeting.